Evelo Biosciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 5yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?
Aug 18
Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03
Aug 11Marella Thorell is the new finance chief of Evelo Biosciences
Jul 18Evelo Biosciences: Hope After Dilution?
Jun 06Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?
Mar 21Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?
Sep 25What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?
Mar 11Evelo Bio secures ~$67.5M capital raise
Jan 29Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis
Jan 07Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares
Dec 15
Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?
Dec 11Evelo Biosciences identifies new lead oncology candidate
Dec 09Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study
Dec 03Evelo Biosciences EPS beats by $0.04
Oct 29CEO
Evelo Biosciences has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | no data | no data | |
| Chief Technical Operations & Quality Officer | 5yrs | no data | no data | |
| VP and Head of Corporate Development & Strategic Integration | 2.7yrs | no data | no data | |
| Head of Research | 5yrs | no data | no data | |
| Chief Medical Officer | 7yrs | US$1.23m | 0.089% $ 8.5 | |
| Senior Director & Immunology Clinical Lead | no data | no data | no data |
5.0yrs
Average Tenure
Experienced Management: EVLO's management team is seasoned and experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/13 05:56 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Gary Nachman | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |